Unilife Corp  

(Public, NASDAQ:UNIS)   Watch this stock  
Find more results for UNIS
3.87
+0.06 (1.57%)
After Hours: 3.85 -0.02 (-0.52%)
May 23, 7:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.59 - 3.95
52 week 1.80 - 5.17
Open 3.73
Vol / Avg. 582,061.00/1.71M
Mkt cap 347.55M
P/E     -
Div/yield     -
EPS -0.73
Shares 89.81M
Beta 1.20
Inst. own 38%
Jul 29, 2013
Q4 2013 Unilife Corp Earnings Release Add to calendar
Jun 7, 2013
Unilife Corp at Jefferies Global Healthcare Conference - 11:00AM EDT - Add to calendar
May 9, 2013
Q3 2013 Unilife Corp Earnings Conference Call
Apr 22, 2013
Q3 2013 Unilife Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -2056.06% -947.67%
Operating margin -1971.24% -914.46%
EBITD margin - -831.44%
Return on average assets -75.04% -60.89%
Return on average equity -142.13% -107.49%
Employees 128 -
Carbon Disclosure Rating - -

Address

250 Cross Farm Lane
YORK, PA 17406
United States - Map
+1-717-3843400 (Phone)
+1-717-3843401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Unilife Corporation (Unilife) is a developer and commercial supplier injectable drug delivery systems. The Company builds long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize its differentiated devices to enable or enhance the clinical development, regulatory approval and lifecycle management of their injectable therapies. The Company device portfolio is suitable for use with brand name, generic or biosimilar drugs and vaccines supplied in either a liquid stable or lyophilized format for delivery via administration routes including subcutaneous injection. Prefilled Syringes with Integrated Needle Retraction, Auto-Injectors, Drug Reconstitution Delivery Systems, Bolus Injectors and Specialized Delivery Systems. It focuses on the design, development, manufacture and supply of a range of retractable syringes. Its principal product is the Unifill ready-to-fill syringe.

Officers and directors

Alan D. Shortall Chief Executive Officer, Executive Director
Age: 59
Bio & Compensation  - Reuters
R. Richard Wieland II Chief Financial Officer, Executive Vice President
Age: 67
Bio & Compensation  - Reuters
Ramin Mojdehbakhsh Ph.D. Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
J. Christopher Naftzger Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Mark V. Iampietro Vice President - Quality and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Slavko James Joseph Bosnjak Independent Non-Executive Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Jeff Carter Non-Executive Director
Age: 54
Bio & Compensation  - Reuters
William Galle Independent Non-Executive Director
Age: 73
Bio & Compensation  - Reuters
John M. Lund Independent Non-Executive Director
Age: 46
Bio & Compensation  - Reuters
Mary Katherine Wold Independent Non-Executive Director
Age: 59
Bio & Compensation  - Reuters